Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

Date Added
October 15th, 2019
PRO Number
Pro00093504
Researcher
Daniel Reuben

List of Studies


Keywords
Cancer/Gastrointestinal
Summary

This study is for older adults with colorectal cancer. The purpose is to determine if low muscle mass plays a role in side effects from chemotherapy.

Institution
MUSC
Recruitment Contact
Nancy McGaha
864-725-7129
nmcgaha@selfregional.org

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Date Added
August 28th, 2019
PRO Number
Pro00086110
Researcher
Daniel Reuben

List of Studies


Keywords
Cancer, Cancer/Gastrointestinal, Drug Studies
Summary

This is a research study to compare the effects and safety, good or bad, of tislelizumab (also known as BGB-A317) plus chemotherapy against placebo (an inactive substance) plus chemotherapy for adults with locally advanced recurrent or metastatic esophageal squamous cell carcinoma to find out which is better. Subjects may continue study treatment during their participation in the study as long as there is no worsening of disease and they don't have intolerable side effects from the study treatment

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clincal-trials@musc.edu

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab

Date Added
February 26th, 2019
PRO Number
Pro00086647
Researcher
Daniel Reuben

List of Studies


Keywords
Cancer, Cancer/Skin
Summary

This study is for patients that have been diagnosed with Merkle Cell Carcinoma. The investigational drug in this study is pembrolizumab. The purpose of this study is to compare the usual approach of post-surgery observation with or without radiation to using pembrolizumab with or without radiation after surgery. Participants can expect to be on this study for a total of 5 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized Phase II Study of Anti-PD1 Antibody (MK-3475 (Pembrolizumab)) Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Date Added
August 9th, 2018
PRO Number
Pro00080885
Researcher
Daniel Reuben

List of Studies


Keywords
Cancer, Cancer/Skin
Summary

This study is for patients that have been diagnosed with Merkel cell carcinoma. The investigational drug in this study is pembrolizumab. This study will compare any good and bad effects of using radiation along with an immunotherapy treatment [MK-3475 (pembrolizumab)] compared with MK-3475 (pembrolizumab) alone. Participants can expect to be in this study for up to 7 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu



-- OR --